Drug intelligence / Profile preview

QBR202

Development stage: Unknown
Lead developer: Xunji Biotechnology
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravitreal

Overview

QBR202 is a long-acting biologic agent designed to inhibit vascular endothelial growth factor (VEGF), currently under development by Beijing Xunji Biotechnology for the treatment of retinal vascular disorders. The drug is primarily indicated for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). By targeting and neutralizing VEGF-A, QBR202 aims to suppress the pathological angiogenesis and vascular permeability that drive vision loss in these conditions. It is administered via intravitreal injection and is currently being evaluated in Phase I clinical trials in China to assess its safety, tolerability, and preliminary efficacy.

Targets

VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on QBR202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QBR202.

Explore the full profile